These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside. Weinstock M; McDermott DF Am Soc Clin Oncol Educ Book; 2015; ():e291-7. PubMed ID: 25993188 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. Labriola MK; Batich KA; Zhu J; McNamara MA; Harrison MR; Armstrong AJ; George DJ; Zhang T Clin Genitourin Cancer; 2019 Jun; 17(3):e513-e521. PubMed ID: 30858035 [TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. Flippot R; Escudier B; Albiges L Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355 [TBL] [Abstract][Full Text] [Related]
8. Current immunotherapeutic strategies in renal cell carcinoma. Amato RJ Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554 [TBL] [Abstract][Full Text] [Related]
9. The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma. Chang AJ; Zhao L; Zhu Z; Boulanger K; Xiao H; Wakefield MR; Bai Q; Fang Y Anticancer Res; 2019 Jun; 39(6):2683-2687. PubMed ID: 31177102 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Gill D; Hahn AW; Sonpavde G; Agarwal N Hum Vaccin Immunother; 2016 Dec; 12(12):2997-3004. PubMed ID: 27494417 [TBL] [Abstract][Full Text] [Related]
11. Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies. Thomas JS; Kabbinavar F Crit Rev Oncol Hematol; 2015 Dec; 96(3):527-33. PubMed ID: 26299335 [TBL] [Abstract][Full Text] [Related]
12. The current state of immune checkpoint inhibitors in the first-line treatment of renal cancer. Rassy EE; Khoury Abboud RM; Ibrahim N; Assi T; Aoun F; Kattan J Immunotherapy; 2018 Sep; 10(12):1047-1052. PubMed ID: 30185138 [TBL] [Abstract][Full Text] [Related]
14. Overview of current and future systemic therapy for metastatic renal cell carcinoma. Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031 [TBL] [Abstract][Full Text] [Related]
15. Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. Venur VA; Joshi M; Nepple KG; Zakharia Y Drug Des Devel Ther; 2017; 11():1175-1182. PubMed ID: 28442891 [TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy for renal cell carcinoma - current status]. Grimm MO; Foller S Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of metastatic renal cell cancer. Fishman M; Seigne J Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet? Guida M; Colucci G Ann Oncol; 2007 Jun; 18 Suppl 6():vi149-52. PubMed ID: 17591810 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence? Giuliani J; Drudi F Cancer Biother Radiopharm; 2012 Oct; 27(8):513-8. PubMed ID: 22738404 [TBL] [Abstract][Full Text] [Related]